| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H20N2 |
| Molecular Weight | 276.3755 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC2=C(C1)C3=C(C=CC=C3)N2CC4=CC=CC=C4
InChI
InChIKey=FQQIIPAOSKSOJM-UHFFFAOYSA-N
InChI=1S/C19H20N2/c1-20-12-11-19-17(14-20)16-9-5-6-10-18(16)21(19)13-15-7-3-2-4-8-15/h2-10H,11-14H2,1H3
| Molecular Formula | C19H20N2 |
| Molecular Weight | 276.3755 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Mebhydrolin (INN) or mebhydroline is a histamine H1-receptor antagonist. It is not available in the United States, but it is available in various other countries under the brand names Bexidal and Diazolin. It is used for symptomatic relief of allergic symptoms caused by histamine release, including nasal allergies and allergic dermatosis.
Approval Year
Doses
AEs
PubMed
Sample Use Guides
Adults and children over 10 years 2-6 tablets daily
Children from 5-10 years 2-4 tablets daily
Children from 2-5 years 1-3 tablets daily
Children up to 2 years 1-2 tablets daily
Treatment should be given in several single doses daily.
Route of Administration:
Oral
